In a NSCLC preclinical study, the depletion of Tregs via an antibody targeting CD25, a surface protein found on a majority of CD4+ Tregs, synergized with carboplatin chemotherapy and significantly extended the survival of tumor-bearing mice compared to chemotherapy alone [59]. The gene discussed is CD4; the disease is neoplasm.